Dr Lal Pathlabs Ltd News

Dr Lal PathLabs up 4% on strong September qtr results; more details here

The uptick in Dr Lal PathLabs's share price came on the back of a healthy September quarter of financial year 2025 (Q2FY25) earnings

Dr Lal PathLabs Q2 results: Profit up by 18.2%, revenue rises by 9.8%

The company, which operates 280 labs across India and is on track to open 15-20 new labs this year as part of its expansion efforts, is also exploring acquisitions in southern India

Dr Lal Path Labs Q2FY25 results: Net profit jumps 18% to Rs 129 cr

The company's consolidated net profit increased 18 per cent year-over-year to Rs 129 crore ($15.4 million), increasing for the sixth quarter in a row

RBI Policy: Will Bank Nifty fall to 50K or hit 52K today? Key levels here

Derivatives market update Oct 09: NSE F&O data shows that retail investors' are most bullish since the Lok Sabha poll outcome in June; their long-short ratio in index futures rose to 1.44.

F&O Insights: IPCA, Divis Lab see bullish bets; 24,700 the key for Nifty

Derivatives market update: 12 stocks including Balrampur Chini, GNFC, India Cement, LIC Housing and National are in F&O ban on Thursday; 2 stocks see buildup up short positions; details here

Dr Lal PathLabs Q1 results: Net profit up by 29.1%, revenue rises by 11.3%

The company's revenue from operations rose to Rs 602 crore in Q1FY25, an 11.3 per cent Y-o-Y growth from Rs 541 crore reported in Q1FY24

Dr Lal PathLabs Q1FY25 results: Net profit rises 28% to Rs 106 cr

Consolidated net profit rose 28 per cent to Rs 106 cr (around $13 million) for the quarter ended June 30, beating analysts' estimate of Rs 99.27 cr, per LSEG

Healthcare at new high; Lupin, Glenmark among 5 stocks for up to 15% upside

5 breakout pharma stocks: Glenmark, Lupin, Laurus Labs, Dr Lal PathLabs and Zydus Life can potentially rally up to 15 per cent, suggest charts.